Table 1.
Demographics and clinical characteristics of study participants.
| Group | Age | Gender | Race | Risk | HCV GT | HCV VL | HIV Ab | HIV VL | TCD4 | CD4% | Systemic corticosteroids | Clinical manifestations of MC vasculitis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal volunteer 1 | 41 | F | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 2 | 34 | M | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 3 | 56 | F | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 4 | 37 | F | Black | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 5 | 42 | M | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 6 | 46 | F | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 7 | 39 | M | Hispanic | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 8 | 45 | M | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 9 | 38 | F | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 10 | 46 | M | White | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 11 | 41 | F | Black | N/A | N/A | N/A | Negative | N/A | ||||
| Normal volunteer 12 | 27 | W | Male | N/A | N/A | N/A | Negative | N/A | ||||
| HIV/HCV 1 | 49 | M | Black | IVDU | 1a | 7,692,310 | Positive | 121 | 1,233 | 45 | ||
| HIV/HCV 2 | 40 | M | Black | MSM | 1a | 4,976,400 | Positive | <50 | 1,460 | 44 | ||
| HIV/HCV 3 | 51 | M | Black | IVDU | 1b | 3,945,420 | Positive | <50 | 727 | 30 | ||
| HIV/HCV 4 | 49 | F | Black | IVDU | 1a | 1,054,510 | Positive | <50 | 794 | 25 | ||
| HIV/HCV 5 | 55 | M | Black | MSM | 1b | 9,504,730 | Positive | <50 | 1,008 | 43 | ||
| HCV 1 | 51 | M | White | IVDU | 1b | 2,500,000 | Negative | N/A | ||||
| HCV 2 | 53 | F | White | IVDU | 1a | 473,000 | Negative | N/A | ||||
| HCV 3 | 51 | M | Black | IVDU | 1 | 441,000 | Negative | N/A | ||||
| HCV 4 | 45 | M | White | IVDU | 1a | 3,820,000 | Negative | N/A | ||||
| HCV 5 | 42 | M | White | IVDU | 2 | 10,900,000 | Negative | N/A | ||||
| HCV 6 | 59 | F | Black | IVDU | 2b | 7,810,000 | Negative | N/A | ||||
| HCV 7 | 70 | M | White | IVDU | 1b | 3,830,000 | Negative | N/A | ||||
| HCV MC Vasc 1 | 56 | M | White | Needlestick | 1a | 3,419,770 | Negative | N/A | Arthralgia, purpura, peripheral neuropathy | |||
| HCV MC Vasc 2 | 52 | M | White | Transfusion acquired | 1a, 1b | 1,864,910 | Negative | N/A | Prednisone 10 mg daily | Arthritis, purpura, peripheral neuropathy | ||
| HCV MC Vasc 3 | 47 | F | White | IVDU | 2b | 2,296,250 | Negative | N/A | Peripheral neuropathy, hematuria | |||
| HCV MC Vasc 4 | 56 | M | White | Intranasal cocaine | 1a | 50,816 | Negative | N/A | Purpura, glomerulonephritis | |||
| HCV MC Vasc 5 | 47 | M | White | Intranasal cocaine | 1a | 932,880 | Negative | N/A | Prednisone 50 mg daily | Purpura, ulcers, mononeuritis | ||
| HCV MC Vasc 6 | 56 | M | White | IVDU | 1a | 100,907 | Negative | N/A | Arthralgia, purpura, peripheral neuropathy | |||
| HCV MC Vasc 7 | 58 | F | White | IVDU | 1 | <615 | Negative | N/A | Prednisone 30 mg daily | Purpura, ulcers, hematuria |
HIV and HCV viral loads were measured by the Versant RNA 3.0 Assay with a lower limit of detection of 50 copies/ml and 615 IU/ml, respectively. qRT-PCR results are shown only for 5 of the 12 healthy volunteers and 6 of the 7 HCV monoinfected subjects due to availability of samples. Samples for the other seven normal volunteer patients were used to validate microarray analysis in Kottilil et al. (14). Additionally, B cell depletion experiments were only done on subsets of individuals as determined by sample availability.